Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Maviret“
Suchtreffer
Begriffe & Kennungen
Maviret · 4.5 · Glecaprevir and pibrentasvir are inhibitors of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP),
Eintrag öffnenMaviret · 4.5 · Glecaprevir and pibrentasvir are substrates of the efflux transporters P-gp and/or BCRP. Glecaprevir is also a
Eintrag öffnenMaviret · 4.5 · Glecaprevir and pibrentasvir are substrates of the efflux transporters P-gp and/or BCRP. Glecaprevir is also a
Eintrag öffnenMaviret · 4.5 · Glecaprevir and pibrentasvir are weak inhibitors of cytochrome P450 (CYP) 3A and uridine glucuronosyltransfera
Eintrag öffnenMaviret · 4.5 · Glecaprevir and pibrentasvir are weak inhibitors of cytochrome P450 (CYP) 3A and uridine glucuronosyltransfera
Eintrag öffnenMaviret · 4.5 · Medicinal product Effect on by therapeutic medicinal areas/possible Cmax AUC Cmin Clinical comments product me
Eintrag öffnenMaviret · 4.5 · Medicinal product by Effect on therapeutic Clinical medicinal Cmax AUC Cmin areas/possible comments product le
Eintrag öffnenMaviret · 4.5 · Patients treated with vitamin K antagonists
Eintrag öffnenMaviret · 4.5 · Patients treated with vitamin K antagonists
Eintrag öffnenMaviret · 4.5 · Potential for Maviret to affect other medicinal products
Eintrag öffnenMaviret · 4.5 · Potential for Maviret to affect other medicinal products
Eintrag öffnenMaviret · 4.5 · Potential for other medicinal products to affect Maviret
Eintrag öffnenMaviret · 4.5 · Significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, UGT1A6, UGT1A9, UGT1A4, UGT2B7, OCT1, OCT2, OAT1, O
Eintrag öffnenMaviret · 4.5 · Significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, UGT1A6, UGT1A9, UGT1A4, UGT2B7, OCT1, OCT2, OAT1, O
Eintrag öffnenMaviret · 4.5 · Table 3 provides the least-squares mean Ratio (90% Confidence Interval) effect on concentration of Maviret and
Eintrag öffnenMaviret · 4.5 · Table 3: Interactions between Maviret and other medicinal products
Eintrag öffnenMaviret · 4.5 · Table 4 provides the least-squares mean Ratio (90% Confidence Interval) effect on concentration of Maviret and
Eintrag öffnenMaviret · 4.5 · Table 4: Interactions between Maviret and other medicinal products
Eintrag öffnenMaviret · 4.5 · Use with strong P-gp/CYP3A inducers Medicinal products that are strong P-gp and CYP3A inducers (e.g., rifampic
Eintrag öffnenMaviret · 4.5 · Use with strong P-gp/CYP3A inducers Medicinal products that are strong P-gp and CYP3A inducers (e.g., rifampic
Eintrag öffnen